A convertible bond of Cogent Biosciences, a biotechnology company developing precision-oncology therapies that target genetically defined tumors and mast-cell diseases.
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|---|---|---|---|---|
| Howard Marks / Oaktree | 69 | New buy | 7,650,000 | $8,994,870 | 0.1% |
| Stanley Druckenmiller / Duquesne | 81 | Added +109% | 2,214,470 | $78,658 | 1.8% |
Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-07-02.